Trial Profile
Multicentre, Prospective, Randomized, Open-label Study Comparing the Efficacy and Safety of CellCept With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Standard Immunosuppression Comprising CellCept and Long-term Continuation of Cyclosporine in Renal Transplant Recipients Receiving Induction by Zenapax and Treated With Corticosteroids for 8 Months
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mycophenolate mofetil (Primary) ; Ciclosporin; Daclizumab; Prednisolone; Prednisolone; Sirolimus
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 23 Feb 2016 New trial record